Affiliations: Istanbul University, Cerrahpasa Faculty of Medicine
Department of Biostatistics, Istanbul, Turkey | Istanbul Science University Medical Faculty,
Department of Medical Biology and Genetics, Istanbul, Turkey | Istanbul Science University Medical Faculty,
Department of Cardiology, Istanbul, Turkey
Note: [] Corresponding author: Assoc. Prof. Belgin Susleyici-Duman,
Istanbul Science University Medical Faculty, Department of Medical Biology and
Genetics, Büyükdere Street No.120, Esentepe-Istanbul, Turkey. Tel.: +90
212 213 64 83; Fax: +90 212 272 34 61; E-mail: belgin.susleyici@bilim.edu.tr
Abstract: Our aim was to determine whether lipoprotein lipase gene PvuII
polymorphism can be considered as an independent risk factor for coronary
artery disease (CAD) by conducting a meta-analysis of all available published
trials, including our own study. In 7 seperate studies, 3289 subjects were
screened for this substitution; meta-analysis included only some of these
individuals. Among the 7 studies, 6 were performed on white subjects, whereas 1
was on patients with Saudi Arabic descent.Subgroup analysis indicated that
individuals with PvuII substitution does not have an increased risk for CAD.
The LPL-PvuII genotype and allele frequency distributions did not differ
significantly between CAD patients and healthy controls. There was no
difference in the distribution of LPL-PvuII genotypes between the healthy
subjects and the patients with CAD. However, no significant differences in
lipid variables (triglyceride and HDL-cholesterol) were determined for the
PvuII polymorphisms in the patients with CAD. No significant differences were
found in serum triglyceride and HDL-cholesterol levels for LPL-PvuII genotypes
when the control and CAD groups were pooled. In conclusion, LPL-Pvu II
polymorphism cannot be used as independent genetic risk factor for CAD.
